Unique immune signatures predict potential cardiometabolic risk in severe COVID-19 patients and COVID-19 recovered individuals
Namal P. M. Liyanage(National Cancer Institute), Nicholas Funderburg(Ohio Department of Health), Yasasvi Wijewantha(The Ohio State University), Janelle Gabriel(The Ohio State University), Emily Bowman(The Ohio State University), Krishanthi Weragalaarachchi(The Ohio State University), Manuja Gunasena(The Ohio State University), Anna E. Vilgelm(The Ohio State University), Anushka Ruwanpathirana(The Ohio State University), Amrendra Kumar(University of Delhi), Sonal Pannu(Oklahoma City University), Dhanuja Kasturiratna(Northern Kentucky University), Joseph S. Bednash(The Ohio State University Wexner Medical Center), Aaren Kettelhut(The Ohio State University), Thorsten Demberg(Baylor College of Medicine)
Cited by 1
Related Papers
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
Microbial translocation, immune activation, and HIV disease
|Trends in Microbiology|2012|393
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
|Nature Medicine|2016|204
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
|New England Journal of Medicine|2022|181